TITLE

Roflumilast: A new phosphodiesterase 4 inhibitor for chronic obstructive pulmonary disease

AUTHOR(S)
Baker, Erica L.; Baker, William L.
PUB. DATE
January 2010
SOURCE
Formulary;Jan2010, Vol. 45 Issue 1, p6
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the use of roflumilast for the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD). Roflumilast is a phosphodiesterase 4 inhibitor under review by the U.S. Food and Drug Administration (FDA). Studies demonstrate that roflumilast improves lung function and has been well tolerated by patients. The most common side effects include nausea, headache and weight loss.
ACCESSION #
47695586

 

Related Articles

  • Safety of Inhaled Anticholinergics for COPD Scrutinized. Elliott, William T. // Primary Care Reports;Nov2008 Pharmacology Watch, p1 

    The article considers the safety of inhaled anticholinergics for the treatment of chronic obstructive pulmonary disease (COPD), which was prompted by a communication from the U.S. Food and Drug Administration (FDA) regarding the safety review of tiotropium. Two studies linking inhaled...

  • Safety of Inhaled Anticholinergics for COPD Scrutinized.  // Neurology Alert;Nov2008 Pharmacology Watch, p1 

    The article reports on the Early Communication issued by the U.S. Food and Drug Administration (FDA) in July 2008 concerning the ongoing safety review of tiotropium drug for the treatment of chronic obstructive pulmonary disease (COPD). Said review aims to investigate the possible association of...

  • Umeclidinium-vilanterol: First once-daily dual bronchodilator for COPD. YOUNG, CARA ALDRIDGE // Pharmacy Today;Feb2014, Vol. 20 Issue 2, p28 

    The article reports on the approval for umeclidinium-vilanterol powder by the U.S. Food & Drug Administration as a dual bronchodilator for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). The contraindications of the use of the drug in patients with asthma are...

  • Pharmacovigilance Analysis of Adverse Psychiatric Events and Suicidality Reported for Roflumilast, an Add-On COPD Therapy. Ali, Ayad K. // British Journal of Pharmaceutical Research;Oct-Dec2013, Vol. 3 Issue 4, p972 

    Aims: Roflumilast is a phosphodiesterase-4-inhibitor used as add-on therapy to long- acting bronchodilators in chronic obstructive pulmonary disease. Although roflumilast is well tolerated, there have been concerns regarding psychiatric problems, including suicide tendencies. This study aims to...

  • Roflumilast.  // AHFS Consumer Medication Information;Apr2018, p1 

    Roflumilast is used in people with severe chronic obstructive pulmonary disease (COPD; a group of diseases that affect the lungs and airways) to reduce the number of episodes or worsening of COPD symptoms. Roflumilast is in a class of medications called phosphodiesterase inhibitors. It works by...

  • Quantitative benefit-harm assessment for setting research priorities: the example of roflumilast for patients with COPD. Puhan, Milo A.; Tsung Yu; Boyd, Cynthia M.; ter Riet, Gerben // BMC Medicine;Jul2015, Vol. 13 Issue 1, p1 

    Background: When faced with uncertainties about the effects of medical interventions regulatory agencies, guideline developers, clinicians, and researchers commonly ask for more research, and in particular for more randomized trials. The conduct of additional randomized trials is, however,...

  • FDA Actions. Elliott, William T. // Infectious Disease Alert;Dec2007, Vol. 27 Issue 3, p2 

    The article reports on drug regulatory actions taken by the U.S. Food and Drug Administration (FDA) as of December 2007. The agency announced warnings on phosphodiesterase type 5 inhibitors like sildenafil, tadalafil and vardenafil, regarding hearing loss. The FDA suggested caution in using the...

  • Salmeterol is now indicated for COPD. Cerrato, Paul L. // RN;May98, Vol. 61 Issue 5, p80 

    Focuses on the approval of the drug salmeterol (Serevent) by the United States (US) Food and Drug Administration, an inhaler used in the treatment of chronic obstructive pulmonary disease (COPD). How the drug should be administered; Adverse reactions towards the drug.

  • Roflumilast Tablets (Daliresp®). Elliott, William T.; Chan, James // Internal Medicine Alert;4/29/2011, Vol. 33 Issue 8, p62 

    The article offers information on the drug Roflumilast, an oral phosphodiesterase 4 (PDE4) inhibitor used to treat chronic osbtructive pulmonary disease (COPD), with its brand name Daliresp from Forest Pharmaceuticals Inc.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics